{"filings":[{"id":734476,"accession_number":"0001104659-26-068002","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-05-29T13:56:10+00:00","items":["7.01","9.01"],"status":"ready","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company will resubmit BLA in coming days after collaborative FDA dialogue aligns on path forward.","FDA will treat resubmission as urgent matter and prioritize review due to high unmet need.","Approximately 8,500 Americans with advanced melanoma die each year; half fail checkpoint inhibitor therapy.","BLA supported by IGNYTE trial data in patients who progressed on anti-PD-1 therapy.","CEO Sushil Patel expressed gratitude to FDA for commitment to supporting patients and innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95092,"accession_number":"0001104659-26-042141","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA issues second CRL for Replimune's RP1 BLA; company plans layoffs and manufacturing scale-back","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA second Complete Response Letter for BLA of RP1 plus nivolumab for advanced melanoma; Replimune disagrees with decision.","Without timely accelerated approval, further development of RP1 not viable; company eliminating jobs and scaling back U.S. manufacturing.","IGNYTE trial: 34% response rate, median duration 24.8 months for RP1 plus nivolumab in patients progressing on anti-PD-1.","Company cites inconsistent FDA process: new review team, contradictions from September 2025 Type A meeting, and lack of communication.","Approximately 8,500 advanced melanoma deaths annually in U.S.; CEO says regulatory failure denies patients needed treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107916,"accession_number":"0001104659-26-009510","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Replimune Q3 net loss $70.9M; cash $269.1M; RP1 BLA PDUFA date April 10, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and short-term investments $269.1M as of Dec 31, 2025; cash runway extended late into Q1 2027.","Net loss for Q3 FY2026 was $70.9M vs $66.3M in prior year quarter; R&D expenses $53.1M.","BLA resubmission for RP1 in anti-PD-1 failed melanoma accepted; FDA PDUFA target action date April 10, 2026.","Amended loan with Hercules: drew $35M, potential additional $120M post-approval; debt repayment delayed to 2027.","Phase 3 IGNYTE-3 confirmatory study for RP1 enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma actively enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107915,"accession_number":"0001104659-26-002721","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Replimune files updated corporate presentation for J.P. Morgan; exhibit content not available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released updated corporate presentation on January 12, 2026.","Presentation to be presented at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.","Presentation covers recent business developments and clinical data for RP1 and RP2 programs.","Exhibit 99.1 text was not provided, preventing detailed analysis of clinical or strategic updates.","No specific financial or clinical figures were disclosed in the 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124329,"accession_number":"0001104659-25-107438","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q2 net loss $83.1M; FDA accepts RP1 BLA resubmission with PDUFA April 10, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $323.6M at Sep 30, 2025, down from $483.8M at Mar 31, 2025.","R&D expenses $57.9M vs $43.4M YoY; S,G&A $26.4M vs $15.5M YoY.","Net loss $83.1M vs $53.1M in prior year quarter.","FDA accepted BLA resubmission for RP1 in advanced melanoma; PDUFA target action date April 10, 2026.","Phase 3 IGNYTE-3 trial enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124328,"accession_number":"0001104659-25-100605","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Replimune's BLA resubmission for RP1 in advanced melanoma; PDUFA April 10, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted resubmission of BLA for RP1 plus nivolumab in advanced melanoma patients who progressed on anti-PD-1 therapy.","PDUFA target action date set for April 10, 2026 under Class II resubmission timeline.","Resubmission addresses the complete response letter received in July 2025; includes additional data and analyses.","Replimune CEO expressed commitment to working closely with FDA to expedite review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141005,"accession_number":"0001104659-25-091066","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune completes Type A FDA meeting for RP1 BLA in melanoma; path forward uncertain","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Completed Type A FDA meeting on Sept 16, 2025 regarding CRL for RP1+nivolumab BLA in advanced melanoma.","Evaluating FDA feedback; accelerated approval path not yet determined.","CEO cites unmet need and compelling IGNYTE trial risk-benefit; committed to working with FDA.","No timeline or resolution provided; stock may remain volatile pending updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141004,"accession_number":"0001104659-25-087464","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Replimune schedules Type A meeting with FDA to discuss RP1 CRL; program viability at risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Type A meeting scheduled to discuss CRL for RP1 BLA in advanced melanoma; briefing submitted with additional analysis.","CEO states without accelerated approval, RP1 program in advanced melanoma, including phase 3 confirmatory trial, will not be viable.","Stockholders voted against amending 2018 Omnibus Incentive Compensation Plan (26.97M for, 35.49M against).","All director nominees elected; PwC ratification and say-on-pay proposals approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141003,"accession_number":"0001104659-25-074989","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q1 FY2026 net loss $86.7M; FDA issues CRL for RP1 BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $86.7M for quarter ended June 30, 2025, vs $53.8M a year ago.","Cash, cash equivalents and short-term investments $403.3M; funding expected into Q4 2026.","FDA issued Complete Response Letter for RP1 BLA in advanced melanoma on July 22, 2025.","R&D expenses $57.8M (up from $43.0M); SG&A $32.6M (up from $14.4M), driven by commercial prep.","Ongoing Phase 3 IGNYTE-3 trial for RP1+nivolumab; Phase 2/3 REVEAL trial for RP2 in uveal melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141002,"accession_number":"0001104659-25-069489","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune receives FDA Complete Response Letter for RP1 BLA in advanced melanoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issues CRL for RP1 + nivolumab; IGNYTE trial deemed not adequate/well-controlled.","CRL cites heterogeneous patient population and need to address confirmatory trial design.","No safety issues raised; Company requests Type A meeting within 30 days.","CEO surprised as issues not raised during mid- or late-cycle reviews.","Without accelerated approval, RP1 development for advanced melanoma patients not viable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158772,"accession_number":"0001104659-25-062122","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Replimune hosts Investor Day on June 24, 2025; updated presentation posted online","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day webcast and updated presentation deck available under Events and Presentations on company website.","No financial results, pipeline updates, or guidance changes were disclosed in the 8-K filing.","Company directs investors to monitor its website for material non-public information per Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158771,"accession_number":"0001104659-25-051847","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q4 net loss $74.1M; RP1 BLA on track for July 22 PDUFA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $74.1M, FY $247.3M; cash $483.8M, runway into Q4 2026 excluding revenue.","BLA for RP1+nivolumab in advanced melanoma on schedule; PDUFA July 22, 2025; no advisory committee.","Commercial infrastructure fully built and ready for launch; distribution channels established.","R&D Q4 $54.0M (+27% YoY); SG&A Q4 $25.4M (+57% YoY) driven by pre-launch scaling.","Investor day June 24; confirmatory Phase 3 IGNYTE-3 enrolling 400 patients globally."],"consensus_eps_estimate":-0.9078,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177183,"accession_number":"0001104659-25-021756","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Replimune appoints Michael Goller to board; enters registration rights with BBA Funds","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Goller appointed to Board on March 5, 2025; board expanded to 10 members.","Goller is an employee of Baker Bros. Advisors LP; received option for 64,000 shares at $12.29.","Company entered Affiliate Registration Rights Agreement with BBA Funds for resale registration of their shares.","BBA Funds participated in June 2024 private placement ($96.7M net) and Nov 2024 public offering ($156M net).","Agreement allows up to one underwritten offering per year, max three total, and up to two offerings/trades per year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177182,"accession_number":"0001104659-25-011851","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q3 net loss $66.3M; FDA accepts RP1 BLA with priority review, PDUFA July 22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted BLA for RP1+nivolumab in advanced melanoma with Priority Review; PDUFA date July 22, 2025.","Net loss $66.3M for fiscal Q3 2025, up from $51.1M in Q3 2024; R&D expense $48.0M.","Cash & investments $536.5M as of Dec 31, 2024, expected to fund operations into Q4 2026.","Public offering raised ~$156M net to support RPx development and potential commercial launch.","First patients enrolled in RP2 registration-directed trial for uveal melanoma and Phase 2 HCC trial."],"consensus_eps_estimate":-0.8013,"consensus_eps_actual":-2.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177181,"accession_number":"0001104659-25-005291","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune BLA for RP1+nivolumab in advanced melanoma accepted with Priority Review; PDUFA July 22, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for RP1 (vusolimogene oderparepvec) plus nivolumab for advanced melanoma; granted Priority Review.","PDUFA action date set for July 22, 2025; no advisory committee meeting currently planned.","BLA supported by primary analysis from IGNYTE trial in anti-PD-1 failed melanoma patients.","Confirmatory Phase 3 IGNYTE-3 trial ongoing with over 100 planned sites globally.","Replimune previously received Breakthrough Therapy designation for this combination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193954,"accession_number":"0001104659-24-125370","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K/A","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune closes $155.8M public offering of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,923,000 common shares at $13.00 and 3,846,184 pre-funded warrants at $12.9999 each, raising ~$155.8M net.","Underwriter's over-allotment option for 1,615,377 additional shares exercised in full.","Pre-funded warrants have $0.0001 exercise price; beneficial ownership cap corrected to 19.99% in this amendment.","Shares and warrants sold pursuant to effective shelf registration; expected closing Nov 27 and Dec 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193958,"accession_number":"0001104659-24-123451","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune prices upsized public offering of ~$140M; 6.9M shares + pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 6,923,000 common shares at $13.00/share and pre-funded warrants for 3,846,184 shares at $12.9999 each.","Gross proceeds ~$140M; net proceeds estimated at ~$155.8M after full exercise of underwriter option.","Leerink Partners sole bookrunner; closing expected Nov 27, 2024.","Underwriter's 30-day option for 1,615,377 additional shares exercised in full."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193957,"accession_number":"0001104659-24-122860","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Replimune reduces ATM offering capacity from $100M to $89M, suspends sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate offering amount cut from $100M to $89M via Amendment No. 2 dated Nov 25, 2024.","Company suspending ATM prospectus; no sales until new prospectus or registration statement filed.","Amendment entered with Leerink Partners LLC; Sales Agreement otherwise remains in effect.","Reduction and suspension are precautionary; no current sales are being made under ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193956,"accession_number":"0001104659-24-121616","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune submits BLA for RP1+nivolumab in advanced melanoma under Accelerated Approval; FDA grants Breakthrough Therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BLA submitted to FDA for RP1 (vusolimogene oderparepvec) + nivolumab in advanced melanoma patients previously treated with anti-PD1.","Submission under Accelerated Approval pathway; based on safety and activity in IGNYTE trial.","FDA granted Breakthrough Therapy designation for RP1 + nivolumab in same setting.","Confirmatory Phase 3 IGNYTE-3 trial enrolling patients with prior anti-PD1 and anti-CTLA-4 therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193955,"accession_number":"0001104659-24-116413","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune reports Q2 FY2025 net loss $53.1M; BLA for RP1 in melanoma on track before year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed pre-BLA meeting with FDA; BLA submission for RP1+nivolumab in anti-PD1 failed melanoma via accelerated approval path on track by end of 2024.","IGNYTE primary analysis: 33.6% ORR at 12 months by modified RECIST 1.1; median DOR from response initiation 21.6 months.","Cash, cash equivalents and short-term investments $432.1M as of Sep 30, 2024; funding operations into H2 2026.","R&D expenses $43.4M, down from $49.1M; net loss $53.1M, improved from $60.0M YoY.","RP2 in uveal melanoma: registration-directed trial with first patient enrollment expected Q1 2025."],"consensus_eps_estimate":-0.8234,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210280,"accession_number":"0001104659-24-097365","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Replimune shareholders elect three Class III directors and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors elected: Sushil Patel (54.6M for), Dieter Weinand (46.9M for), Madhavan Balachandran (54.6M for).","Ratification of PricewaterhouseCoopers as auditor for FY2025: 62.7M for, 4.4K against.","Say-on-pay advisory approval passed: 53.6M for, 1.0M against.","Frequency of say-on-pay set at every 1 year: 54.2M for 1 year, 421.6K for 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210279,"accession_number":"0001104659-24-087035","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune Q1 FY2025: $53.8M net loss, $469.1M cash; RP1 BLA on track for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $53.8M for Q1 ended June 30, 2024, up from $49.6M YoY; R&D expenses $43.0M versus $40.4M.","Cash, cash equivalents and short-term investments $469.1M; $96.7M net PIPE financing supports operations into 2H 2026.","Pre-BLA meeting with FDA scheduled for September 2024; RP1 BLA submission planned for 2H 2024.","First patient enrollment in Phase 3 confirmatory IGNYTE-3 trial for RP1 in anti-PD1 failed melanoma expected Q3 2024.","Protocol finalized for registration-directed study of RP2 in uveal melanoma; Phase 2 HCC trial first patient expected 2H 2024."],"consensus_eps_estimate":-0.7677,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228586,"accession_number":"0001104659-24-071078","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Replimune raises $100M in PIPE to fund RP1 commercialization; BLA filing on track for 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 5.67M shares at $8.82/share and 5.67M pre-funded warrants at $8.819/warrant.","Gross proceeds ~$100M; expected closing June 14, 2024.","Proceeds to fully scale up for RP1 commercial launch in skin cancers, potential path to profitability.","Led by life-sciences institutional investor; Redmile, RTW, Boxer Capital participated.","RP1 IGNYTE trial in anti-PD1 failed melanoma showed strong data; BLA submission expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228585,"accession_number":"0001104659-24-068948","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Replimune reports positive IGNYTE primary analysis: ORR 33.6% in anti-PD1 failed melanoma; BLA submission planned 2H2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary analysis shows ORR 33.6% (modified RECIST 1.1) and 32.9% (RECIST 1.1) by independent central review; all responses >6 months, median DOR >35 months.","BLA submission intended for 2H2024; confirmatory IGNYTE-3 trial first patient expected Q3 2024.","Safety: predominantly Grade 1-2 constitutional events; no Grade 5 events; low incidence of Grade 3-4 incidents.","Data improves on investigator-assessed results presented at ASCO 2024; FDA-requested RECIST 1.1 analysis included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228584,"accession_number":"0001104659-24-067556","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Replimune presents positive RP1/RP2 data at ASCO: 32.7% ORR in melanoma, BLA on track for 2H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RP1+nivolumab in anti-PD-1 failed melanoma (n=156) showed 32.7% ORR by investigator; median duration of response >36 months.","In primary resistant patients (n=94) ORR 34%; in anti-PD-1+anti-CTLA-4 progressors (n=66) ORR 27.3%.","RP2 in uveal melanoma (n=17) showed 29.4% ORR and 58.8% DCR as monotherapy or with nivolumab; registration-directed trial planned.","Company expects central review results Q2 2024; BLA submission for RP1 in 2H 2024; Phase 3 IGNYTE-3 to start before BLA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228583,"accession_number":"0001104659-24-062296","cik":1737953,"company_name":"Replimune Group, Inc.","ticker":"REPL","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Replimune posts Q4 net loss $55.1M; RP1 melanoma BLA on track for 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.1M for Q4 FY2024; full-year net loss $215.8M vs $174.3M prior year.","Cash, equivalents & investments $420.7M; cash runway projected into 2H 2026.","Primary analysis of IGNYTE trial (RP1 + nivolumab) in anti-PD1 failed melanoma expected Q2 2024.","BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024 after positive FDA CMC meeting.","First patient enrollment in Phase 3 IGNYTE-3 confirmatory trial expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":384788377.4723404,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}